ECSP045467A - Nuevos anticuerpos dirigidos contra factores tisulares como anticoagulantes - Google Patents

Nuevos anticuerpos dirigidos contra factores tisulares como anticoagulantes

Info

Publication number
ECSP045467A
ECSP045467A EC2004005467A ECSP045467A ECSP045467A EC SP045467 A ECSP045467 A EC SP045467A EC 2004005467 A EC2004005467 A EC 2004005467A EC SP045467 A ECSP045467 A EC SP045467A EC SP045467 A ECSP045467 A EC SP045467A
Authority
EC
Ecuador
Prior art keywords
tissular
anticoagulants
factors
directed against
antibodies directed
Prior art date
Application number
EC2004005467A
Other languages
English (en)
Spanish (es)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045467(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ECSP045467A publication Critical patent/ECSP045467A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EC2004005467A 2002-05-01 2004-11-30 Nuevos anticuerpos dirigidos contra factores tisulares como anticoagulantes ECSP045467A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37656602P 2002-05-01 2002-05-01

Publications (1)

Publication Number Publication Date
ECSP045467A true ECSP045467A (es) 2005-01-28

Family

ID=29401364

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2004005467A ECSP045467A (es) 2002-05-01 2004-11-30 Nuevos anticuerpos dirigidos contra factores tisulares como anticoagulantes
EC2004005468A ECSP045468A (es) 2002-05-01 2004-11-30 Nuevas proteínas de fusión con trombomodulina dirigidas contra factores tisulares como anticoagulantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
EC2004005468A ECSP045468A (es) 2002-05-01 2004-11-30 Nuevas proteínas de fusión con trombomodulina dirigidas contra factores tisulares como anticoagulantes

Country Status (29)

Country Link
US (3) US7250168B2 (enExample)
EP (2) EP1503785B1 (enExample)
JP (2) JP4567437B2 (enExample)
KR (2) KR101013697B1 (enExample)
CN (2) CN100412090C (enExample)
AR (1) AR039515A1 (enExample)
AT (2) ATE427121T1 (enExample)
AU (2) AU2003225256B2 (enExample)
BR (2) BR0304659A (enExample)
CA (2) CA2483910A1 (enExample)
CR (1) CR7584A (enExample)
DE (2) DE60326970D1 (enExample)
DK (2) DK1503785T3 (enExample)
EC (2) ECSP045467A (enExample)
ES (2) ES2354419T3 (enExample)
HK (1) HK1080372A1 (enExample)
IL (3) IL164733A0 (enExample)
MX (2) MXPA04010795A (enExample)
NO (2) NO20035848L (enExample)
NZ (2) NZ536242A (enExample)
PE (1) PE20040597A1 (enExample)
PL (2) PL210582B1 (enExample)
PT (2) PT1549341E (enExample)
RS (2) RS102404A (enExample)
RU (2) RU2320366C2 (enExample)
TW (1) TWI343388B (enExample)
UA (2) UA85996C2 (enExample)
WO (2) WO2003093422A2 (enExample)
ZA (2) ZA200409694B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188830B1 (en) 1999-06-02 2010-01-20 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein ,nr10
EP1221482B1 (en) 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
EP2351855A1 (en) 2000-09-26 2011-08-03 Duke University RNA aptamers and methods for identifying the same
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
RS102404A (sr) * 2002-05-01 2006-12-15 Schering Aktiengesellschaft Nova antitela koja ciljaju tkivni faktor kao antikoagulanti
AU2003256299A1 (en) 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7833978B2 (en) * 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
CA2563176A1 (en) 2004-04-22 2005-11-10 Regado Biosciences, Inc. Improved modulators of coagulation factors
CN103665168A (zh) * 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
WO2008039206A2 (en) * 2005-10-05 2008-04-03 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
ATE485052T1 (de) * 2006-04-07 2010-11-15 Novo Nordisk Healthcare Ag Kovalenter faktor vii-gewebefaktor-komplex
AU2007255753B2 (en) 2006-06-08 2013-01-17 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
UA97961C2 (ru) * 2006-10-06 2012-04-10 Асахи Касеи Фарма Корпорейшн Способ лечения и/или улучшения диссеминированного внутрисосудистого свертывания крови
US9649499B2 (en) * 2007-03-28 2017-05-16 Medtronic ATS Medical, Inc. Method for inhibiting platelet interaction with biomaterial surfaces
AU2008300516A1 (en) * 2007-09-20 2009-03-26 Bracco Imaging Spa Method for the preparation of new oligoclonal antibodies
RU2596397C2 (ru) 2007-12-05 2016-09-10 Чугаи Сейяку Кабусики Кайся Терапевтическое средство от зуда
US8333973B2 (en) * 2008-01-02 2012-12-18 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP2321338A1 (en) * 2008-08-14 2011-05-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
US20110262466A1 (en) * 2008-10-16 2011-10-27 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2230251A1 (en) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antibodies specifically active in the coronary plaque and method for their identification
EP2470201A4 (en) * 2009-08-28 2013-01-30 Bayer Healthcare Llc COFACTORS ENABLING THE THROMBINIC ACTIVATION OF FACTOR VII AND THEIR USES
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
JP6143297B2 (ja) * 2010-06-04 2017-06-07 チウムバイオ・カンパニー・リミテッドＴｉｕｍＢｉｏ Ｃｏ．， Ｌｔｄ． 第ｖｉｉ因子活性を有する融合タンパク質
EP3281956A3 (en) 2010-06-15 2018-04-18 Genmab A/S Human antibody drug conjugates against tissue factor
CN103179982A (zh) * 2010-08-05 2013-06-26 科学与工业研究委员会 具有溶血栓和抗凝血性质的蛋白融合构建体
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
BR112017022101A2 (pt) 2015-04-14 2018-07-31 Chugai Seiyaku Kabushiki Kaisha composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo
FI3284480T3 (fi) 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
WO2016176440A2 (en) * 2015-04-28 2016-11-03 Saint Louis University Thrombin-thrombomodulin fusion proteins as protein c activators
US11085031B2 (en) 2016-04-28 2021-08-10 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant
TW201831508A (zh) * 2016-11-16 2018-09-01 美商拜耳保健有限責任公司 紅血球標靶因子ｖｉｉｉ及其使用方法
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CA3099547A1 (en) 2018-05-07 2019-11-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
WO2020070237A1 (en) * 2018-10-04 2020-04-09 Thrombosis And Coagulation Ab Method for the determination of protein s levels
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
IL293099B2 (en) 2019-11-20 2025-07-01 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
CN114686443B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用
CN114686444B (zh) * 2020-12-31 2024-05-31 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5589173A (en) * 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US4912207A (en) * 1987-05-06 1990-03-27 Washington University DNA clone of human thrombomodulin and portions thereof
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
EP0458903A4 (en) * 1989-02-17 1992-06-17 Codon Soluble analogs of thrombomodulin
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5256770A (en) * 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
US5466668A (en) * 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
KR930008093B1 (ko) * 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
JPH0578397A (ja) * 1991-01-29 1993-03-30 Sumitomo Pharmaceut Co Ltd 血栓溶解タンパク質
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5916874A (en) * 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
AU752730B2 (en) * 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
JP2003527861A (ja) * 2000-03-16 2003-09-24 ジェネンテック・インコーポレーテッド 増強した抗血液凝固能を持つ抗組織因子抗体
US6632791B1 (en) * 2000-06-21 2003-10-14 Schering Aktiengesellschaft Thrombomodulin analogs for pharmaceutical use
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003057911A2 (en) 2002-01-08 2003-07-17 Bayer Healthcare Ag Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
RS102404A (sr) * 2002-05-01 2006-12-15 Schering Aktiengesellschaft Nova antitela koja ciljaju tkivni faktor kao antikoagulanti

Also Published As

Publication number Publication date
HK1080372A1 (zh) 2006-04-28
US20080020965A1 (en) 2008-01-24
PT1503785E (pt) 2011-01-17
RS102404A (sr) 2006-12-15
PE20040597A1 (es) 2004-10-06
CN100412090C (zh) 2008-08-20
AR039515A1 (es) 2005-02-23
KR20050045944A (ko) 2005-05-17
RU2004135306A (ru) 2005-07-10
PT1549341E (pt) 2009-05-29
ATE427121T1 (de) 2009-04-15
EP1549341A4 (en) 2006-10-18
ZA200409694B (en) 2006-02-22
IL164733A0 (en) 2005-12-18
DK1503785T3 (da) 2011-02-07
ECSP045468A (es) 2005-01-28
DE60334538D1 (de) 2010-11-25
WO2003092602A3 (en) 2004-08-26
US7250168B2 (en) 2007-07-31
UA81114C2 (en) 2007-12-10
EP1503785A4 (en) 2007-02-14
RU2004135308A (ru) 2005-08-10
ATE484524T1 (de) 2010-10-15
ES2354419T3 (es) 2011-03-14
JP4460443B2 (ja) 2010-05-12
AU2003225256A1 (en) 2003-11-17
EP1503785B1 (en) 2010-10-13
AU2003225256B2 (en) 2009-06-04
CN1665534A (zh) 2005-09-07
MXPA04010795A (es) 2005-03-07
CR7584A (es) 2006-05-30
JP2005532045A (ja) 2005-10-27
WO2003093422A2 (en) 2003-11-13
KR20050045945A (ko) 2005-05-17
EP1503785A2 (en) 2005-02-09
IL164732A0 (en) 2005-12-18
US7622122B2 (en) 2009-11-24
NZ536242A (en) 2006-04-28
DK1549341T3 (da) 2009-07-06
MXPA04010851A (es) 2005-02-14
AU2003225255B2 (en) 2008-07-31
BR0304659A (pt) 2004-09-21
AU2003225255A1 (en) 2003-11-17
WO2003093422A3 (en) 2004-07-15
ZA200409692B (en) 2006-07-26
KR101013697B1 (ko) 2011-02-10
TW200307043A (en) 2003-12-01
RU2320366C2 (ru) 2008-03-27
BR0304660A (pt) 2005-06-07
JP4567437B2 (ja) 2010-10-20
NO20035848L (no) 2004-02-27
IL164733A (en) 2011-05-31
TWI343388B (en) 2011-06-11
UA85996C2 (ru) 2009-03-25
DE60326970D1 (de) 2009-05-14
WO2003092602A2 (en) 2003-11-13
US20040063632A1 (en) 2004-04-01
PL210582B1 (pl) 2012-02-29
CN100563709C (zh) 2009-12-02
ES2323056T3 (es) 2009-07-06
CA2483909A1 (en) 2003-11-13
CN1665526A (zh) 2005-09-07
NO20035849L (no) 2004-02-27
US20080019985A1 (en) 2008-01-24
PL373945A1 (en) 2005-09-19
PL373960A1 (en) 2005-09-19
EP1549341A2 (en) 2005-07-06
KR101080587B1 (ko) 2011-11-04
RU2345789C2 (ru) 2009-02-10
JP2005538046A (ja) 2005-12-15
US7622457B2 (en) 2009-11-24
CA2483910A1 (en) 2003-11-13
RS104504A (sr) 2007-02-05
NZ536243A (en) 2006-06-30
EP1549341B1 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
ECSP045467A (es) Nuevos anticuerpos dirigidos contra factores tisulares como anticoagulantes
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
BRPI0419206A (pt) artigo absorvente
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
AR054233A1 (es) Composiciones de anticuerpos igg2
MX2019004573A (es) Metodos para evitar eventos cardiovasculares mediante la reduccion de la proproteinas convertasa subtilisina kexina 9 (pcsk9).
WO2010056765A3 (en) Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
AR032643A1 (es) Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares
AR032403A1 (es) Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
ATE524125T1 (de) Platte und schrauben zur behandlung von knochenfrakturen
DE502005004113D1 (de) Lanzettensystem mit Sterilschutz
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
ATE426437T1 (de) Fingerprotektor und damit ausgerusteter sporthandschuh
BRPI0516764B8 (pt) hemostato
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
DE502005005659D1 (de) Verkürzte wundheilungsprozesse mittels neuartiger faservliese
DK1562681T3 (da) Sok
ES2119411T3 (es) Combinaciones de proteinas y anticoagulantes tromboliticamente activos, y usos de los mismos.
DE602005012539D1 (de) Faserstrukturen mit einem nanopartikeladditiv
ATE416676T1 (de) Vaskuläre okklusionsvorrichtung
EA200300849A1 (ru) Способы лечения или профилактики кожных заболеваний с помощью cd2-связывающих агентов
ATE451077T1 (de) Künstliches blutgefäss
ATE514815T1 (de) Faserstrukturen mit zusatz mit geringer oberflächenenergie
DK1926458T3 (da) Indretning, strimmel og beklægning til behandling af hud- og subkutane vævslidelser, og til reparation af sportsskader og fremgangsmåde til fremstilling af samme
WO2006114105A3 (en) Use of modified factor vii for treating bleeding